Business Context and Reporting Period
Company: Varex Imaging Corporation (VREX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended September 27, 2024 (52 weeks)
Business Overview: Varex is a leading designer and manufacturer of X-ray imaging components, including X-ray tubes, flat panel detectors, and linear accelerators. The company operates two segments: Medical (components for diagnostic imaging systems) and Industrial (security inspection, non-destructive testing, and irradiation). The company serves a concentrated customer base, with its top five customers accounting for approximately 41% of total revenue in fiscal 2024.
Key Financial Metrics
| Metric (in millions) | Fiscal 2024 | Fiscal 2023 | Change |
|---|---|---|---|
| Total Revenues | $811.0 | $893.4 | (9)% |
| Gross Profit | $256.9 | $290.3 | (12)% |
| Operating Income | $32.1 | $77.1 | (58)% |
| Net (Loss) Income | $(47.2) | $48.7 | N/A |
| Net (Loss) Income Attributable to Varex | $(47.7) | $48.2 | N/A |
| Diluted EPS | $(1.17) | $1.08 | N/A |
| Operating Cash Flow | $47.3 | $108.4 | (56)% |
| Total Debt Outstanding (Net) | $443.4 | $442.6 | 0.2% |
| Cash and Cash Equivalents | $168.7 | $152.6 | 10.6% |
| Backlog | $299.0 | N/A | N/A |
Margins: Total gross margin decreased to 31.7% in 2024 from 32.5% in 2023. Medical gross margin was 30.4%, while Industrial gross margin was 35.0%.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 9% year-over-year. The Medical segment drove this decline with a 14% drop ($91.6 million), primarily due to lower sales in China and decreased demand for fluoroscopy, oncology, and dental applications. The Industrial segment grew 4% ($9.2 million) due to increased security inspection product sales.
- Profitability Reversal: The company reported a net loss of $47.2 million in 2024, compared to net income of $48.7 million in 2023. This was largely driven by a significant increase in income tax expense ($52.2 million) resulting in an effective tax rate of 1,044.0%, compared to a tax benefit in 2023.
- Geographic Performance: APAC revenues fell 18% ($56.7 million) due to decreased X-ray tube and detector sales. Americas and EMEA revenues declined 5% and 4%, respectively.
- Operating Expenses: Total operating expenses increased 5% to $224.8 million. Selling, general, and administrative (SG&A) expenses rose 7% to $137.8 million, increasing as a percentage of revenue to 17.0% due to fixed costs, litigation expenses, and severance costs.
Guidance, Outlook, Risks, and Contingencies
- China Market Impact: The company notes that the Chinese government's anti-corruption campaign in the healthcare industry has negatively impacted Medical sales. Management expects this to continue at some level through fiscal year 2025, though they remain optimistic about long-term opportunities.
- Debt Maturity and Liquidity: Varex has $200.0 million of 4.00% Convertible Senior Unsecured Notes maturing in June 2025. Management anticipates refinancing this obligation using a combination of borrowings under its Revolving Credit Facility and cash. The company maintains $155.0 million in availability under its Revolving Credit Facility and $20.0 million under its Equipment Credit Facility, both currently undrawn.
- Goodwill Impairment: In Q4 2024, indicators of possible impairment existed due to reduced demand and stock price declines. However, a quantitative analysis determined that the fair value of both reporting units exceeded their carrying amounts, resulting in no impairment charges for the year.
- Legal Proceedings: The company is involved in disputes regarding its joint venture VEC Imaging GmbH & Co. KG in Germany, involving shareholder resolution validity and management control. Additionally, there are ongoing disputes with a joint venture partner in Saudi Arabia. Management does not believe these will have a material adverse effect at this time.
- Trade and Tariffs: The company faces risks from U.S.-China trade tensions. U.S. tariff exclusions are set to expire on May 31, 2025. The company is implementing "local-for-local" sourcing strategies to mitigate these risks.
Key Facts for Investor Verification
- Refinancing Risk: Verify the company's ability to refinance the $200 million Convertible Notes due in June 2025, given the current market environment and the conversion price being significantly above the trading price.
- Tax Provision Volatility: Investigate the drivers of the 1,044% effective tax rate in 2024, specifically the increase in valuation allowances against U.S. federal deferred tax assets and foreign losses.
- China Exposure: Monitor the duration and severity of the Chinese anti-corruption campaign's impact on the Medical segment, which accounts for the majority of the revenue decline.
- Customer Concentration: Note that the top five customers represent 41% of revenue, with Canon Medical Systems alone accounting for 18%. Verify the stability of these key relationships.
- Joint Venture Disputes: Track the resolution of the legal disputes in Germany (VEC) and Saudi Arabia, as these could divert management attention and increase costs.